Zacks Investment Research downgraded Selecta Biosciences Inc (NASDAQ:SELB) to Hold in a report released today.
- Updated: October 15, 2016
Zacks Investment Research has downgraded Selecta Biosciences Inc (NASDAQ:SELB) to Hold in a report released on 10/12/2016.
Previously on 9/20/2016, Zacks Investment Research reported about Selecta Biosciences Inc (NASDAQ:SELB) raised the target price from $0.00 to $15.00. At the time, this indicated a possible upside of 0.13%.
Yesterday Selecta Biosciences Inc (NASDAQ:SELB) traded 1.97% higher at $16.00. The company’s 50-day moving average is $14.07 and its 200-day moving average is $13.39. The last stock close price is up 23.44% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 5,768 shares of the stock were exchanged, down from an average trading volume of 27,334
See Chart Below
Selecta Biosciences Inc has a 52 week low of $10.26 and a 52 week high of $18.88 The company’s market cap is currently $0.
About Selecta Biosciences Inc (NASDAQ:SELB)
Selecta Biosciences, Inc. is a clinical-stage biopharmaceutical company. The Company uses synthetic vaccine particle (SVP) technology to discover and develop targeted therapies that are designed to modulate the immune system to treat rare and serious diseases. It operates in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases segment. Its SVP technology encapsulates an immunomodulator in biodegradable nanoparticles to induce antigen-specific immune tolerance to mitigate the formation of anti-drug antibodies (ADAs) in response to life-sustaining biologic drugs. Its SVP technology has a range of applications to both manage biologic drugs and enable therapies. It offers product candidates in programs, including SVP for immune tolerance and SVP for immune stimulation. Its SVP for immune stimulation includes Smoking cessation and relapse prevention (SEL-070), and human papillomavirus (HPV)-associated cancer (SEL-701).
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.